If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date. When tofacitinib(1, 3, 5, 10,and 15 mg BID) is used in a 12-week study in active RA subjects, to evaluate subjects’ quality of life(QOL)and functional status. The results showed also, a significant increase in levels of cholesterol. subjects, to evaluate the safety and tolerability of all dose levels of tofacitinibversus placebo. The use of the eHealthMe site and its content is at your own risk. hemoglobin (Hb) and hematocrit (HCT) in the 2nd group (Arthritis group). Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. Different individuals may respond to medication in different ways. Our phase IV clinical studies alone cannot establish cause-effect relationship. WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.ĭISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. Our analysis results are available to researchers, health care professionals, patients ( testimonials), and software developers ( open API). Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. We study millions of patients and 5,000 more each day. doi:10.With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. Thrombocytosis: Management and treatment.Ĭenters for Disease Control and Prevention. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Methotrexate tablets, USP.Īvina-zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Factors associated with myelosuppression related to low-dose methotrexate therapy for inflammatory rheumatic diseases. Thrombocytosis in rheumatoid arthritis: JAK2V617F-positive essential thrombocythemia. Thrombocythemia and thrombocytosis.Īyvaz OC, Yavasoglu I, Kadikoylu G, et al. National Institutes of Health: National Heart, Lung, and Blood Institute. National Organization for Rare Disorders.
0 kommentar(er)
